ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Safety"

  • 2017 American Transplant Congress

    Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.

    M. Casagrande, K. Cunningham, C. Tseng, C. D'Agostino, L. Wong, C. Richardson.

    Pharmacy, Northwestern Memorial Hospital, Chicago, IL

    Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…
  • 2017 American Transplant Congress

    Donor Derived Transmission Events in 2015-2016: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).

    C. Wolfe,1 M. Clark,2 S. Tlusty,2 D. Kaul,1 M. Michaels.1

    1DTAC, Richmond; 2United Network for Organ Sharing, Richmond

    The OPTN DTAC, a multidisciplinary committee, evaluates potential donor derived transmission events (PDDTE), including mostly infections (I) & malignancies (M), to assess for likelihood of…
  • 2017 American Transplant Congress

    A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.

    G. Banham,1,2 S. Flint,3 N. Torpey,2 P. Lyons,1 D. Shanahan,3 A. Gibson,3 A.-M. O'Sullivan,2 R. Jones,1,2,3 L. Devey,3 A. Richards,3 L. Erwig,3 C. Savage,3 K. Smith,1,2 R. Henderson,3 M. Clatworthy.1,2

    1Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 3GlaxoSmithKline, Stevenage, United Kingdom

    This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…
  • 2017 American Transplant Congress

    Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.

    M. Pereira,1 F. Silveira,2 G. Papanicolaou,3 A. Langston,4 R. Avery,5 A. Wijatyk,6 J. Wu,6 M. Boeckh,7 F. Marty,8 S. Villano.9

    1Columbia University Medical Center, New York, NY; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4Winship Cancer Institute, Atlanta, GA; 5Johns Hopkins University, Baltimore, MD; 6Shire, Lexington, MA; 7Fred Hutchinson Cancer Research Center, Seattle, WA; 8Brigham and Women's Hospital, Boston, MA; 9Shire (At Time of Study), Wayne, PA

    Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
  • 2017 American Transplant Congress

    Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.

    T. Rege,1 K. Hatahet,1 A. Gillespie,1 M. Ghanta,1 I. Lee,1 K. Qureshi,1 K. Lau,2 S. Karhadkar,2 A. DiCarlo,2 S. Constantinescu,1 S. Rao.1

    1Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; 2Surgery, Temple University, Philadelphia, PA

    Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…
  • 2017 American Transplant Congress

    Improving Value by Standardizing the Use of IVIG Amongst Pediatric Solid Organ Transplant (SOT) Patients.

    J. Sawyer,1 J. Bucuvalas,2 L. Danziger-Isakov,3 J. Gossett,3 L. Burkhart,3 A. Lorts.3

    1Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati; 2Division of Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati; 3Solid Organ Transplant Center, Cincinnati Children's Hospital Medical Center, Cincinnati

    Background: Given the high cost of pharmaceuticals (i.e. IVIG), we sought to determine if unnecessary variation in drug use may be an opportunity to improve…
  • 2017 American Transplant Congress

    Safety of Liver Donation from Living Donors with Sickle Cell Trait.

    H. Elsiesy,1,2 M. Sturdevant,1 W. Al-Hamoudi,1 H. Elbeshbeshy,1 M. Al Sebayel,1 A. Jaafari,1 F. Abaalkhail.1,2

    1Liver Trasplantation, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 2Medicine, Alfaisal University, Riyadh, Saudi Arabia; 3Gastroenterology, King Saud University, Riyadh, Saudi Arabia

    Background:Living donor liver transplant (LDLT) is an important source of organs particularly with the cadaveric organ shortage. It is the main source of liver transplant…
  • 2017 American Transplant Congress

    Risk of Major Bleeding in Solid Organ Transplant Recipients Taking Calcineurin Inhibitors Concomitantly with Direct Oral Anticoagulants Compared to Warfarin.

    J. Hazelcorn, R. Yau, N. Sabagha, M. Moaddab, M. Manson.

    Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX

    Purpose: Direct oral anticoagulants (DOAC) and calcineurin inhibitors (CNI) are both substrates of CYP 3A metabolism; therefore, the purpose of this study is to assess…
  • 2016 American Transplant Congress

    Assessing Vaccination Status in Transplant Candidates and Recipients: Current Status and Challenges to Successful Implementation.

    H. Leung, K. Cameron, B. Ho, M. Ison.

    Northwestern University Feinberg School of Medicine, Chicago, IL.

    Background: Vaccines are safety and efficacy of vaccines in transplant candidates and recipients. Several studies have demonstrated significant underutilization of vaccines which increases the risk…
  • 2016 American Transplant Congress

    A Multidisciplinary Approach to Reviewing Patient Care in Abdominal Transplantation.

    S. Lerner, M. Resta-Flarer, R. Shapiro, S. Florman, L. Kim-Schluger, V. Nair.

    Mount Sinai Hospital, New York, NY.

    Purpose: Unbiased review of patient care in solid organ transplantation is difficult but essential for improving patient safety. In October 2013 we created a process…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences